Added a comment in Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
Interesting points Joel. Regarding non-dihdropyridine CCBs, this is a still a relatively unanswered question whether they offer specific advantages over DHP-CCBs. At one time, I heard Bayer (promoting Adalat XL at the time) was considering a head-to-head trial with diltiazem XC. But of course, it never happened and so the theory never progressed beyond George Bakris' original work (a good article to add this repository). The apparent advantage of DHPs over non-DHPs for blood pressure potency also didn't help the cause of non-DHPs. Jordan
Added a comment in A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
A pivotal trial that changed it all for me
Added a comment in Empagliflozin and renal outcomes: further insights in to the renal protection of SGLT2 inhibitors
Still nothing yet Joel. I would expect that we will see something soon in a high-impact journal. Jordan
Added a comment in Unable to load article details (1376)
Thanks for sharing Tushar and TOUNJ!
Added a comment in Unable to load article details (1270)
My pleasure. I hope you like it. We are always adding new material to the site. For older material, it's probably best to use flash on a desktop computer. Newer resources work on all platforms. Jordan
The person has not posted any comments on the site yet
